Lenz Therapeutics, Inc. (LENZ) intrinsic value & 10-year financials
Lenz Therapeutics, Inc. (LENZ) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 7 fiscal years revenue reached to $19.1M, with an average return on invested capital of -120.5%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $3.27
- Market cap
- $94.2M
- Revenue (FY2025)
- $19.1M
- ROIC (10-yr avg)
- -120.5%
- Free cash flow (FY2025)
- -$70.0M
LENZ 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $19.1M | -$82.1M | -$2.85 | -$70.0M | -477.5% | -41.0% |
| FY2024 | $0 | -$49.8M | -$2.34 | -$59.9M | — | -63.6% |
| FY2023 | — | -$124.7M | -$2.19 | -$100.9M | — | -108.1% |
| FY2022 | — | -$101.1M | -$1.84 | -$94.6M | — | -80.3% |
| FY2021 | — | -$70.8M | -$2.45 | -$58.6M | — | -469.7% |
| FY2020 | — | -$68.4M | — | -$10.3M | — | 39.9% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
LENZ Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
LENZ Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -59.5% ROIC.
LENZ Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
LENZ Therapeutics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.